CERo confirms research partnership and $40 million funding round
Category: #health  By Mateen Dalal  Date: 2020-03-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

CERo confirms research partnership and $40 million funding round

CERo Therapeutics, Inc., the privately-owned biopharma firm, recently announced that it will be collaborating for research with Lyell Immunopharma, Inc. for the development of next-gen cell-based immunotherapy solutions to treat solid tumors. CERo also announced that it completed its Series A private financing, securing $40 million.

Apparently, the terms of the agreement demands Lyell and CERo to collaborate for pursuing the proof-of-concept studies for the new class of cell-based therapeutics, mainly directed against solid tumors. The CER-T technology of CERo directs the immune cells to occupy complementary and novel tumor cell clearance pathways that are designed to facilitate sustained and deeper responses against all the broad tumor classes.

The Chief Executive Officer and Co-founder of CERo, Daniel Corey, MD, commented that the company’s technology tends to combine several forms of tumor cell clearance and further introducing all of them into single cells to be able to largely expand the therapeutic potential.

Corey further added that Lyell stands as an ideal partner for CERo with its advanced T-cell capabilities. The company believes that both the platforms exhibit powerful therapeutic synergies.

Lyell Immunopharma’s Chief Executive Officer and Founder, Rick Klausner, MD, stated that CERo has been developing an innovative therapeutic class by leveraging the understandings from synthetic biology and innate immunology. 

For the record, Lyell Immunopharma Inc. is essentially a cell therapy firm that is dedicated to developing and understanding technologies helping in overcoming the basic barriers to other curative therapies. The company has placed its focus on advancing science of functionality, target specificity and T-cell differentiation to be able to build curative treatments for different human diseases.

The Series A private financing had included Milky Way Investments Group Limited, Sequoia Capital China, ARCH Venture Partners, Lyell Immunopharma, Inc., as well as the existing shareholders of CERo and has raised $40 million. The proceeds secured from the financing are now being used for the expansion of startup operations and advancing the propriety CER-T technology platform of the company into the clinic.  
 

Source Credit- https://www.cero.bio/news/press-releases/031820/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

40% of COVID-19 patients are asymptomatic, a new CDC report claims
40% of COVID-19 patients are asymptomatic, a new CDC report claims
By Mateen Dalal

The ongoing coronavirus pandemic has wreaked havoc worldwide. Dismissed as a slight by the world initially, the virus shocked the scientific and medical communities alike, with the rapid rate of spreading. Very little information about the novel coro...

AI-centric study abroad platform Edvoy launched by IEC Abroad in India
AI-centric study abroad platform Edvoy launched by IEC Abroad in India
By Mateen Dalal

AI oriented study abroad platform, Edvoy, based out of UK, has reportedly declared its launch in India.  Edvoy, created by IEC Abroad, is a free digital platform that provides impartial advice, support, and content to prospective international s...

Centuria announces Augusta Capital takeover offer to be unconditional
Centuria announces Augusta Capital takeover offer to be unconditional
By Mateen Dalal

  Acceptance to takeover represent 65.86% of Augusta’s shares Takeover provide shareholders with NZ$0.22 in cash and 0.392 Centuria stapled securities for every share of Augusta Centuria’s assets under management will increase b...